Clinical trial
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell…
NCT00397488 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00397488 |
|---|---|
| Title | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium |
| Official title | Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 78 |
| Start date | Sep 1, 2006 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Nov 9, 2006 |
| Last update posted | Jan 25, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: